共 50 条
Antiarrhythmic drug therapy for sustained ventricular arrhythmias complicating acute myocardial infarction
被引:54
|作者:
Piccini, Jonathan P.
[1
]
Schulte, Phillip J.
[1
]
Pieper, Karen S.
[1
]
Mehta, Rajendra H.
[1
]
White, Harvey D.
[3
]
de Werf, Frans Van
[4
,5
]
Ardissino, Diego
[6
]
Califf, Robert M.
[2
]
Granger, Christopher B.
[1
]
Ohman, E. Magnus
[1
]
Alexander, John H.
[1
]
机构:
[1] Duke Univ, Med Ctr, Duke Clin Res Inst, Durham, NC 27706 USA
[2] Duke Univ, Med Ctr, Duke Translat Med Inst, Durham, NC USA
[3] Auckland City Hosp, Green Lane Cardiovasc Serv, Auckland, New Zealand
[4] Univ Hosp Gasthuisberg, B-3000 Louvain, Belgium
[5] Leuven Coordinating Ctr, Louvain, Belgium
[6] Parma Hosp, Parma, Italy
关键词:
ventricular arrhythmia;
antiarrhythmic drug therapy;
clinical trials;
acute coronary syndrome;
ventricular tachycardia;
ventricular fibrillation;
PROPENSITY SCORE;
BETA-BLOCKERS;
MORTALITY;
TRIAL;
AMIODARONE;
FIBRILLATION;
TACHYCARDIA;
DYSFUNCTION;
LIDOCAINE;
FAILURE;
D O I:
10.1097/CCM.0b013e3181fd6ad7
中图分类号:
R4 [临床医学];
学科分类号:
1002 ;
100602 ;
摘要:
Objective: Few data exist to guide antiarrhythmic drug therapy for sustained ventricular tachycardia/ventricular fibrillation after acute myocardial infarction. The objective of this analysis was to describe the survival of patients with sustained ventricular tachycardia/ventricular fibrillation after myocardial infarction according to antiarrhythmic drug treatment. Design and Setting: We conducted a retrospective analysis of ST-segment elevation myocardial infarction patients with sustained ventricular tachycardia/ventricular fibrillation in Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes (GUSTO) IIB and GUSTO III and compared all-cause death in patients receiving amiodarone, lidocaine, or no antiarrhythmic. We used Cox proportional-hazards modeling and inverse weighted estimators to adjust for baseline characteristics, beta-blocker use, and propensity to receive antiarrhythmics. Due to nonproportional hazards for death in early follow-up (0-3 hrs after sustained ventricular tachycardia/ventricular fibrillation) compared with later follow-up (>3 hrs), we analyzed all-cause mortality using time-specific hazards. Patients and Interventions: Among 19,190 acute myocardial infarction patients, 1,126 (5.9%) developed sustained ventricular tachycardia/ventricular fibrillation and met the inclusion criteria. Patients received lidocaine (n = 664, 59.0%), amiodarone (n = 50, 4.4%), both (n = 110, 9.8%), or no antiarrhythmic (n = 302, 26.8%). Results: In the first 3 hrs after ventricular tachycardia/ventricular fibrillation, amiodarone (adjusted hazard ratio 0.39, 95% confidence interval 0.21-0.71) and lidocaine (adjusted hazard ratio 0.72, 95% confidence interval 0.53-0.96) were associated with a lower hazard of death-likely evidence of survivor bias. Among patients who survived 3 hrs, amiodarone was associated with increased mortality at 30 days (adjusted hazard ratio 1.71, 95% confidence interval 1.02-2.86) and 6 months (adjusted hazard ratio 1.96, 95% confidence interval 1.21-3.16), but lidocaine was not at 30 days (adjusted hazard ratio 1.19, 95% confidence interval 0.77-1.82) or 6 months (adjusted hazard ratio 1.10, 95% confidence interval 0.73-1.66). Conclusion: Among patients with acute myocardial infarction complicated by sustained ventricular tachycardia/ventricular fibrillation who survive 3 hrs, amiodarone, but not lidocaine, is associated with an increased risk of death, reinforcing the need for randomized trials in this population. (Crit Care Med 2011; 39:78-83)
引用
收藏
页码:78 / 83
页数:6
相关论文